PDF herunterladen
Pharmacopsychiatry 2019; 52(01): 07-15
DOI: 10.1055/s-0043-124872
Review
© Georg Thieme Verlag KG Stuttgart · New York

Comparative Efficacy and Safety of Antipsychotic Drugs for Tic Disorders: A Systematic Review and Bayesian Network Meta-Analysis

Chunsong Yang   *
1   Department of Pharmacy, Evidence-Based Pharmacy Center, West China Second Hospital, Sichuan University
2   Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education
,
Zilong Hao   *
3   Department of Neurology, West China Hospital, Sichuan University, Chengdu, China
,
Ling-Li Zhang
1   Department of Pharmacy, Evidence-Based Pharmacy Center, West China Second Hospital, Sichuan University
2   Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education
,
Cai-Rong Zhu
4   West China School of Public Health, Sichuan University
,
Ping Zhu
4   West China School of Public Health, Sichuan University
,
Qin Guo
5   Department of Pediatrics, West China Second Hospital, Sichuan University
› Institutsangaben
Weitere Informationen

Publikationsverlauf

received 02. September 2017
revised 04. Dezember 2017

accepted 10. Dezember 2017

Publikationsdatum:
05. März 2018 (online)

Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Objective The purpose of this study was to evaluate the efficacy and safety of antipsychotic drugs for tic disorders (TDs) in a network meta-analysis.

Methods PubMed, Embase, Cochrane Library, and 4 Chinese databases were searched. Randomized controlled trials (RCTs) evaluating the efficacy of antipsychotic drugs for TDs were included.

Results Sixty RCTs were included. In terms of tic symptom score, compared with placebo, haloperidol, risperidone, aripiprazole, quetiapine, olanzapine, and ziprasidone can significantly improve tic symptom score (standardized mean differences [SMD] ranged from −12.32 to −3.20). Quetiapine was superior to haloperidol, pimozide, risperidone, tiapride, aripiprazole, and penfluridol for improving tic symptom score (SMD ranged from −28.24 to −7.59). Compared with tiapride, aripiprazole could significantly improve tic symptom score (SMD=−4.27). Compared with all other drugs, penfluridol was not effective. Atypical antipsychotics were generally well tolerated.

Conclusions Atypical antipsychotics (risperidone and aripiprazole) appear to be the most robust evidence-based options for the treatment of TDs. Quetiapine may be a promising therapy. Ziprasidone and olanzapine are also effective, but the evidence is lacking. Further high-quality directly comparing different pharmacological treatment studies are justified.

Key words

tic disorder - antipsychotic drug - systematic review - network meta-analysis

* Chunsong Yang and Zilong Hao contributed equally to this study.


Supplementary Material

    Supporting Information for this article is available online at http:// doi.org/10.1055/s-0043-124872
  • Supplementary Material
 

  • References

  • 1 Plessen KJ. Tic disorders and Tourette’s syndrome. Eur Child Adolesc Psychiatry 2013; 22 (Suppl. 01) S55-S60
    PubMedGoogle Scholar
  • 2 Cavanna AE, Termine C. Tourette syndrome. Adv Exp Med Biol. 2012; 724: 375-383
    PubMedGoogle Scholar
  • 3 Jimenez-Shahed J. Tourette syndrome. Neurol Clin. 2009; 27: 737-755
    CrossrefPubMedGoogle Scholar
  • 4 Conelea CA, Woods DW, Zinner SH. et al. The impact of Tourette syndrome in adults: Results from the Tourette syndrome impact survey. Community Ment Health J. 2013; 49: 110-120
    CrossrefPubMedGoogle Scholar
  • 5 Jalenques I, Galland F, Malet L. et al. Quality of life in adults with Gilles de la Tourette syndrome. BMC Psychiatry 2012; 12: 109
    CrossrefPubMedGoogle Scholar
  • 6 Roessner V, Plessen KJ, Rothenberger A. et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry 2011; 20: 173-196
    PubMedGoogle Scholar
  • 7 Evans J, Seri S, Cavanna AE. The effects of Gilles de la Tourette syndrome and other chronic tic disorders on quality of life across the lifespan: a systematic review. Eur Child Adolesc Psychiatry 2016; 25: 939-948
    CrossrefPubMedGoogle Scholar
  • 8 Knight T, Steeves T, Day L. et al. Prevalence of tic disorders: A systematic review and meta-analysis. Pediatr Neurol. 2012; 47: 77-90
    CrossrefPubMedGoogle Scholar
  • 9 Murphy TK, Lewin AB, Storch EA. et al. Practice parameter for the assessment and treatment of children and adolescents with tic disorders. J Am Acad Child Adolesc. Psychiatry. 2013; 52: 1341-1359
    CrossrefPubMedGoogle Scholar
  • 10 Pringsheim T, Doja A, Gorman D. et al. Canadian guidelines for the evidence-based treatment of tic disorders: Pharmacotherapy. Can J Psychiatry. 2012; 57: 133-143
    CrossrefPubMedGoogle Scholar
  • 11 Gilbert DL, Batterson JR, Sethuraman G. et al. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry. 2004; 43: 206-214
    CrossrefPubMedGoogle Scholar
  • 12 Yoo HK, Joung YS, Lee JS. et al. A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry. 2013; 74: e772-e780
    CrossrefPubMedGoogle Scholar
  • 13 Ghanizadeh A, Haghighi A. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: A randomized double blind clinical trial. Child Psychiatry Hum Dev. 2014; 45: 596-603
    CrossrefPubMedGoogle Scholar
  • 14 Bruggeman R, van der Linden C, Buitelaar JK. et al. Risperidone versus pimozide in Tourette’s disorder: A comparative double-blind parallel-group study. J Clin Psychiatry. 2001; 62: 50-56
    CrossrefPubMedGoogle Scholar
  • 15 Yang C, Hao Z, Zhu C. et al. Interventions for tic disorders: An overview of systematic reviews and meta analyses. Neurosci Biobehav Rev. 2016; 63: 239-255
    CrossrefPubMedGoogle Scholar
  • 16 Li T, Puhan MA, Vedula SS. et al. Network meta-analysis highly attractive but more methodological research is needed. BMC Med 2011; 9: 79
    CrossrefPubMedGoogle Scholar
  • 17 Paschou P. The genetic basis of Gilles de la Tourette Syndrome. Neurosci Biobehav Rev. 2013; 37: 1026-1039
    CrossrefPubMedGoogle Scholar
  • 18 Yan WW. A review of diagnostic and statistical manual of mental disorder-III. Foreign Med Sci 1981; 2: 5-9
    PubMedGoogle Scholar
  • 19 Pringsheim T, Marras C. Pimozide for tics in Tourette’s syndrome. Cochrane Database Syst Rev. 2009; 15: 1-15
    PubMedGoogle Scholar
  • 20 Leckman JF, Towbin KE, Ort SI. Clinical assessment of tic disorder severity. In: Cohen DJ. ed. Tourette’s Syndrome and Tic Disorders. New York: John Wiley & Sons; 1988: 55-78
    Google Scholar
  • 21 World Health Organization. The ICD-10 Classification of Mental and Behavioral Disorders Diagnostic Criteria for Research. Geneva: WHO; 1993
    Google Scholar
  • 22 The Branch of Psychiatry of Chinese Medical Association. Chinese Classification and Diagnostic Criteria of Mental Disorders-3 (CCMD-3)​​. Shandong: Science and Technology Press of Shandong Province; 2001
    Google Scholar
  • 23 Leckman JF, Riddle MA, Hardin MT. et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry. 1989; 28: 566-573
    CrossrefPubMedGoogle Scholar
  • 24 Leckman JF, Towbin KE, Ort SI. Clinical assessment of tic disorder severity. In: Cohen DJ. ed. Tourette’s Syndrome and Tic Disorders. New York: John Wiley & Sons; 1988: 55-78
    Google Scholar
  • 25 Higgins JPT, Green S.eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration; 2011; Available at www.cochrane-handbook.org
    PubMed
  • 26 Egger M. Davey Smith G. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
    CrossrefPubMedGoogle Scholar
  • 27 Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004; 23: 3105-3124
    CrossrefPubMedGoogle Scholar
  • 28 Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998; 7: 434-445
    PubMedGoogle Scholar
  • 29 Bucher HC, Guyatt GH, Griffith LE. et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-691
    CrossrefPubMedGoogle Scholar
  • 30 Shapiro E, Shapiro AK, Fulop G. et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette’s syndrome. Arch Gen Psychiatry 1989; 46: 722-730
    CrossrefPubMedGoogle Scholar
  • 31 Sallee FR, Dougherty D, Sethuraman G. et al. Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette’s syndrome. Biol Psychiatry 1996; 40: 1044-1050
    CrossrefPubMedGoogle Scholar
  • 32 Sallee FR, Nesbitt L, Jackson C. et al Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry. 1997; 154: 1057-1062
    CrossrefPubMedGoogle Scholar
  • 33 Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. Am J Psychiatry. 1978; 135: 585-587
    CrossrefPubMedGoogle Scholar
  • 34 Shapiro AK, Shapiro E. Controlled study of pimozide vs. placebo in Tourette’s syndrome. J Am Acad Child Psychiatry 1984; 23: 161-173
    CrossrefPubMedGoogle Scholar
  • 35 Onofrj M, Paci C, D’Andreamatteo G. et al. Olanzapine in severe Gilles de la Tourette syndrome: A 52-week double-blind cross-over study vs. low-dose pimozide. J Neurol 2000; 247: 443-436
    CrossrefPubMedGoogle Scholar
  • 36 Sallee FR, Kurlan R, Goetz CG. et al Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000; 39: 292-299
    CrossrefPubMedGoogle Scholar
  • 37 Scahill L, Leckman JF, Schultz RT. et al. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology 2003; 60: 1130-1135
    CrossrefPubMedGoogle Scholar
  • 38 Dion Y, Annable L, Sandor P. et al. Risperidone in the treatment of Tourette syndrome: A double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2002; 22: 31-39
    CrossrefPubMedGoogle Scholar
  • 39 Duan BW, Li MZ. The efficacy of haloperidol and tiapride for the treatment of Tourette syndrome. Chinese Community Doctors 2008; 13: 25
    PubMedGoogle Scholar
  • 40 Lu ZX, Shi L, Li ZJ. A control study of paliperidone versus haloperidol in the treatment of tic disorders in children. China & Foreign Medical Treatment 2015; 10: 7-9
    PubMedGoogle Scholar
  • 41 Zhang Y. Penfluridol (hidden treatment drug) vs. haloperidol for Tourette syndrome. China Pharmacy 2007; 18: 1803-1804
    PubMedGoogle Scholar
  • 42 Huang WJ. A control study of olanzapine and haloperidol in the treatment for tic disorders in children. Medical Journal of Chinese People’s Health 2012; 24: 2863-2893
    PubMedGoogle Scholar
  • 43 Ji WD, Li Y, Li N. et al. Olanzapine for treatment of Tourette syndrome: a double-blind randomized controlled trial. Chinese Journal of Clinical Rehabilitation 2005; 9: 66-68
    PubMedGoogle Scholar
  • 44 Xiong H, Xu J, Peng Z. et al. A control study of ziprasidone and haloperidol in the treatment for Tourette syndrome. Journal of Clinical and Experimental Medicine 2010; 9: 1267-1274
    PubMedGoogle Scholar
  • 45 Wang HL, Gao CH, Yang WB. et al. A control study of risperidone and haloperidol in the treatment for Tourette syndrome. Chinese Journal of Modern Drug Application 2009; 3: 106-107
    PubMedGoogle Scholar
  • 46 Zhang Y, Xu P, Yang Y. A comparative study of risperidone oral solution and haloperidol in the treatment of Tourette’s syndrome. Journal of Psychiatry 2010; 23: 171-173
    PubMedGoogle Scholar
  • 47 Zhang H, Huang HZ, Lin GD. A randomized controlled study of risperidone and aripiprazole in treatment of children with tic disorder. Clinical Focus 2015; 12: 1393-1396
    PubMedGoogle Scholar
  • 48 Zheng SQ, Li RJ, Ding YF. Clinical control study of risperidone and haloperidol in the treatment for Tourette syndrome. Nervous Diseases and Mental Health 2006; 6: 279-281
    PubMedGoogle Scholar
  • 49 Wu ZM, Ren CB. Clinical Observation of risperidone and haloperidol in the treatment of Tourette Syndrome in children. Journal of Psychiatry 2008; 21: 452-453
    PubMedGoogle Scholar
  • 50 Lv CB. Clinical Research of the efficacy of risperidone and haloperidol in the treatment of Tourette Syndrome. Chinese Community Doctors 2011; 13: 37-38
    PubMedGoogle Scholar
  • 51 Zhu QX. The comparison of the effect of risperidone and tiapride in the treatment of children with Tourette’s Syndrome. Jilin Medical Journal 2012; 33: 6502-6503
    PubMedGoogle Scholar
  • 52 Tan QE, Wu BR, Wang HH. et al. A control study of risperidone in the treatment for Tourette syndrome. J Clin Psychol Med 2004; 14: 42-43
    PubMedGoogle Scholar
  • 53 Yao HX, Bao HH, Ou YH. et al. Controlled study of risperidone in treatment of Tourette syndrome. J Clin Psychol Med 2005; 15: 42-43
    PubMedGoogle Scholar
  • 54 Cui YH, Zheng Y. A control observation of refractory Tourette syndrome treated with risperidone. J Clin Psychol Med 2007; 17: 371-373
    PubMedGoogle Scholar
  • 55 Li N, Lei XF, Du JJ. Effect of risperidone for Tourette Syndrome in children. Journal of Applied Clinical Pediatrics 2010; 25: 1604-1605
    PubMedGoogle Scholar
  • 56 Yan Q, Ma PL. Analysis of the clinical data in treatment of Tourette syndrome with risperidone. J Clin Psychosom Dis 2015; 21: 136-137
    PubMedGoogle Scholar
  • 57 Li YD, Luo YN, Wu HS. et al. A comparison of treatment of tic disorder with risperidone and haloperidol. Chin J Rehabil Theory Practice 2006; 12: 844-845
    PubMedGoogle Scholar
  • 58 Huang HZ, Lin JS, Li YH. et al. Clinical study of risperidone and haloperidol in treating Tourette Syndrome. Hebei Medicine Journal 2006; 12: 547-549
    PubMedGoogle Scholar
  • 59 Xu GH. A comparison of treatment of tic disorder with risperidone. Strait Pharmaceutical Journal 2005; 17: 154-154
    PubMedGoogle Scholar
  • 60 Guo JH, Guo SQ. Risperidone oral solution vs. haloperidol in the treatment of childhood tic disorder. Evaluation and Analysis of Drug-Use in Hospitals of China 2011; 11: 459-460
    PubMedGoogle Scholar
  • 61 Zhou KY, Wen FQ, Chen T. et al. A comparative study on risperidone and haloperidol in the treatment of Tourette syndrome. Chinese Journal of Practical Pediatrics 2004; 19: 488-490
    PubMedGoogle Scholar
  • 62 Zhang SC. Clinical research of the effect of risperidone in the treatment for Tourette syndrome with 39 cases. Modern Medicine & Health 2010; 26: 2932-2933
    PubMedGoogle Scholar
  • 63 Yang ZJ. The therapeutic efficacy and safety of tiapride and haloperidol in treatment of Tourette syndrome. Journal of Clinical Pediatrics 2012; 30: 1051-1053
    PubMedGoogle Scholar
  • 64 Zheng QF, Zhao DY, Zhang GY. et al. The observation of the effect of tiapride in the treatment of children with Tourette’s syndrome. Hebei Medical Journal 2012; 34: 2666
    PubMedGoogle Scholar
  • 65 Diao LW. The efficacy of tiapride and haloperidol in the treatment of Tourette syndrome. Applied Journal of General Practice 2008; 6: 196
    PubMedGoogle Scholar
  • 66 Li FM. The therapeutic efficacy and safety of tiapride in treatment of Tourette syndrome. Jilin Medical Journal 2013; 34: 465
    PubMedGoogle Scholar
  • 67 Wang Y, Chen GH. Clinical observation of the treatment of Tourette Syndrome with tiapride and haloperidol. Chinese Journal of Practical Nervous Diseases 2013; 16: 83-84
    PubMedGoogle Scholar
  • 68 Li HM. Comparison of clinical efficacy and safety between tiapride and haloperidol in treatment of Tourette syndrome. Drugs & Clinic 2013; 28: 919-921
    PubMedGoogle Scholar
  • 69 Zhao ZL, Guo P, Guo H. A comparative study of aripiprazole and haloperidol for the treatment of tic disorders in children. World Health Digest 2011; 8: 111-113
    PubMedGoogle Scholar
  • 70 Liu YY, Chen YH, Chen H. et al. A control study of aripiprazole and tiapride treatment for tic disorders in children. Chinese Journal of Contemporary Pediatrics 2010; 12: 421-424
    PubMedGoogle Scholar
  • 71 Xu XX. The efficacy of aripiprazole in treatment of Tourette syndrome. World Latest Medicine Information 2015; 15: 77-78
    PubMedGoogle Scholar
  • 72 Zhang Y, Su J, Hu ZJ. et al. Comparison of clinical efficacy and safety between aripiprazole and tiapride in treatment of Tourette syndrome. Shandong Medical Journal 2014; 54: 44-46
    PubMedGoogle Scholar
  • 73 Chen ZM, Lei QH. Comparative study of aripiprazole and haloperidol in the treatment of tic disorder. Medical Journal of Chinese People’s Health 2012; 24: 402-453
    PubMedGoogle Scholar
  • 74 Ren ZB, Jin WD, Wang HQ. A comparative study of aripiprazole and haloperidol treatment for tic disorders in children. Chinese Journal of Nervous and Mental Diseases 2012; 38: 222-224
    PubMedGoogle Scholar
  • 75 Guo F, Qin X, Guo SQ. et al. Aripiprazole and haloperidol in the treatment of tic disorder of childhood. China Journal of Health Psychology 2013; 21: 1767-1768
    PubMedGoogle Scholar
  • 76 Wang YH, Chen ZM, Wang XS. A comparative study of the effect of aripiprazole and tiapride treatment for tic disorders in children. Shandong Medical Journal 2013; 53: 58-59
    PubMedGoogle Scholar
  • 77 Gao R, Zhou YD, Huang ZY. et al. A comparative study of aripiprazole and haloperidol treatment for tic disorders in children. Sichuan Mental Health 2013; 26: 300-302
    PubMedGoogle Scholar
  • 78 Zheng QM, Li YD, Deng LH. et al. A comparative study of aripiprazole orally disintegrating tablets and Haloperidol treatment for tic disorders. Jilin Medical Journal 2015; 36: 2995-2997
    PubMedGoogle Scholar
  • 79 Sun Y, Wang HP, Duan LF. The clinical efficacy and safety of aripiprazole in the treatment of tic disorder. China Medicine and Pharmacy 2014; 4: 64-65+113
    PubMedGoogle Scholar
  • 80 Zhou W, Zhang YM, Zhou CX. A control analysis of aripiprazole and haloperidol treatment for tic disorders in children. Medical Information 2015; 28: 230-231
    PubMedGoogle Scholar
  • 81 Liang YZ, Zheng Y, Zhang SJ. et al. A control study of quetiapine treatment for Tourette syndrome in children. Journal of Clinical Psychiatry 2006; 16: 292
    PubMedGoogle Scholar
  • 82 Zhang Y, Li XY, Wang Y. A comparative study of quetiapine in the treatment of tic disorder in children. Journal of Psychiatry 2008; 21: 21-23
    PubMedGoogle Scholar
  • 83 Sui GH. A comparative study of quetiapine and haloperidol in the treatment of tic disorder in children. Jilin Medical Journal 2015; 36: 707-708
    PubMedGoogle Scholar
  • 84 Yanlin Yang. A control study of quetiapine and haloperidol in the treatment of tic disorder in children. Journal of Clinical Psychosomatic Diseases 2011; 17: 494-496
    PubMedGoogle Scholar
  • 85 Zhang G. Clinical analysis of sulpiride treatment for Tourette syndrome in children. For all Health 2013; 7: 146-147
    PubMedGoogle Scholar
  • 86 Cavanna AE, Seri S. Tourette’s syndrome. BMJ 2013; 20: 1-6
    PubMedGoogle Scholar
  • 87 Budman CL. The role of atypical antipsychotics for treatment of Tourette's syndrome: An overview. Drugs 2014; 74: 1177-1193
    CrossrefPubMedGoogle Scholar